AAP
LUCD icon

Arax Advisory Partners’s Lucid Diagnostics LUCD Stock Holding History

Arax Advisory Partners’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$135 Buy
+117
New +$149 ﹤0.01% 3591
2025
Q4 		– Sell
-399
Closed -$403 – 4342
2025
Q3 		$403 Buy
+399
New +$436 ﹤0.01% 3386

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Arax Advisory Partners's LUCD Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Lucid Diagnostics (LUCD) in Q1 2026: 117 shares worth $135. The stake represents ﹤0.01% of the portfolio and ranks #3591 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in LUCD as recently as Q3 2025.

Arax Advisory Partners first reported a position in LUCD in Q3 2025 and has held it in 2 quarters since. The position peaked at $403 in Q3 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Arax Advisory Partners held 117 shares of Lucid Diagnostics worth $135 as of Q1 2026.
  • Lucid Diagnostics was a new Arax Advisory Partners position in Q1 2026.
  • Lucid Diagnostics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3591 holding.
  • Arax Advisory Partners first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Lucid Diagnostics position peaked at $403 in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.